# Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer

> **NCT02064582** · PHASE2 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 7 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Leuprolide acetate
- **RADIATION:** radiation

## Key facts

- **NCT ID:** NCT02064582
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2018-06-09
- **Final completion:** 2018-06-09
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2020-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02064582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02064582, "Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02064582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*